Biocon Case Study Analysis

docx

School

Rutgers University *

*We aren’t endorsed by this school

Course

Subject

Marketing

Date

Jan 9, 2024

Type

docx

Pages

Uploaded by PresidentHorsePerson1028

Biocon Case Study Analysis Prepared for Professor Ozge Ergin Marketing for Managers Prepared by Tyrel Samson November 5, 2023

Case Summary In the summer of 2006, Biocon faced a critical decision regarding the launch of its proprietary drug, BIOMab, for head and neck cancer treatment in India. The Drug Controller General of India (DCGI) was about to grant permission for its marketing. Biocon's CEO, Mazumdar-Shaw, needed to decide whether to postpone the launch for further phase 3 trials to gather more evidence for efficacy and safety or proceed with an early launch. The marketing and product launch strategy was also not fully defined. Company Biocon, founded in 1978 as a joint venture between Irish Biocon Biochemicals and Dr. Mazumdar-Shaw, initially focused on manufacturing and exporting enzymes. It evolved into a biotech company with a strong presence in the global biopharma market. Biocon's strategic shift led to a successful IPO, crossing the 1 billion marks. BIOMab was a significant proprietary drug for head and neck cancer, discovered by accident in Cuba. Competition The primary competitor for BIOMab was Erbitux, developed in the USA, with strong phase-3 trial results and three years of market usage. Merck was also exploring clinical trials for Erbitux in the context of head and neck cancer. Despite Erbitux's established history and phase 3 results, BIOMab had potential advantages, including a 100% response rate in combination with chemotherapy and no skin rash. Consumer The target market for BIOMab was predominantly in India's private healthcare sector (80%). Most customers would be paying out of pocket, and BIOMab would likely be used in conjunction with radiotherapy or chemotherapy, limiting the potential market to about 20,000 of the projected 190,000 patients.

Price Determining the right pricing strategy for BIOMab was challenging due to a lack of price elasticity data and the unique Indian market conditions. Possible pricing strategies included pricing higher than Erbitux based on superior trial results, offering an "Indian brand discount," or setting a price that balanced affordability with corporate objectives. Concerns existed about pricing too low, which could affect credibility. - 4000-5000 per dose - “Indian discount” 1000 per dose. Product Biocon considered different launch strategies for BIOMab, including launching it alongside a group of cancer generics or launching it separately. They were concerned about their lack of experience in the industry and the need to increase sales capabilities. - Launch BIOMab immediately? - Launch BIOMab with Cancer Generics simultaneously? - Launch cancer generics first then BIOMab? Promotion The promotional strategy for BIOMab was not fully defined. Biocon intended to leverage the Indian origin and story to market the product, but there was a need to establish connections with patients and doctors and build a track record in marketing such a product. - Traditional Biocon  CFA  wholesaler  retail/hospital pharmacy  doctor) because doctors typically recommended these pharmacies to patients. - Direct to oncologist through refrigerated packaging. - Pros and Cons to both – doctors typically have close relationships with hospital pharmacies.

Your preview ends here

Eager to read complete document? Join bartleby learn and gain access to the full version

Access to all documents
Unlimited textbook solutions
24/7 expert homework help

Should Biocon launch BIOMab immediately or conduct phase-3 trials before launch? - Biocon faces a critical decision in choosing whether to launch BIOMab immediately or conduct phase-3 trials. To make this decision, it should consider the following factors: - Phase-2 results, although sufficient for DCGI approval, may not be adequate to compete with the established Erbitux. - Launching immediately could help Biocon gain a first-mover advantage. - Phase-3 trials would provide additional evidence of efficacy and safety, potentially building stronger credibility. - Develop a detailed launch plan for BIOMab, including the product portfolio, pricing, channel, and communication decisions. Launch BIOMab immediately or simultaneously with a group of cancer generics. - Pricing: Consider pricing BIOMab competitively against Erbitux, with an optional "Indian brand discount." - Channel: Evaluate the effectiveness and efficiency of both the traditional and direct distribution channels, taking into account refrigeration and handling requirements. - Communication: Create a comprehensive communication plan that leverages BIOMab's unique Indian origin and story to build trust with patients and doctors. Highlight the advantages of BIOMab over Erbitux, such as its 100% patient response rate and absence of skin rash. What role does BIOMab play in Biocon’s overall strategy? BIOMab holds a pivotal role in Biocon's strategy to transition from an enzyme-focused company to a fully functional biotech company. Its success in launching BIOMab would: - Establish Biocon as a key player in the biopharmaceutical industry, marked by its IPO's success. - Position Biocon as the first Indian company to launch and market a proprietary drug in India, with the potential to significantly impact the fight against head and neck cancer in the Indian population.

- Enable unique opportunities for Biocon through its joint venture with CIMAB, offering a proprietary product pipeline. - Address the high incidence of head and neck cancer in India, especially among lower-income blue-collar workers who use tobacco and cigarettes.

Related Documents

Textbook review question #3.docx

week 1 discussion.docx

Adidas Entering Esports@@@.pptx

External Analysis - Walmart.pptx

Chap009.pdf

Luxor Case Study Assignment.docx

Gap Case Study Report.docx

study guide 4.docx

BUS-FPX3030_Assessment3-1.docx

Homework 5 MGT 249.docx

Small Business Management Group Project Sophia Wiest.docx

1.png

Recommended textbooks for you

Purchasing and Supply Chain Management

Operations Management

ISBN:9781285869681

Author:Robert M. Monczka, Robert B. Handfield, Larry C. Giunipero, James L. Patterson

Publisher:Cengage Learning

MARKETING 2018

Marketing

ISBN:9780357033753

Author:Pride

Publisher:CENGAGE L

Principles of Management

Management

ISBN:9780998625768

Author:OpenStax

Publisher:OpenStax College

Marketing

ISBN:9780357033791

Author:Pride, William M

Publisher:South Western Educational Publishing

SEE MORE TEXTBOOKS

Recommended textbooks for you

Purchasing and Supply Chain Management
Operations Management
ISBN:9781285869681
Author:Robert M. Monczka, Robert B. Handfield, Larry C. Giunipero, James L. Patterson
Publisher:Cengage Learning
MARKETING 2018
Marketing
ISBN:9780357033753
Author:Pride
Publisher:CENGAGE L
Principles of Management
Management
ISBN:9780998625768
Author:OpenStax
Publisher:OpenStax College
Marketing
Marketing
ISBN:9780357033791
Author:Pride, William M
Publisher:South Western Educational Publishing